194 related articles for article (PubMed ID: 28802754)
1. Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand.
Hayman DTS; Marshall JC; French NP; Carpenter TE; Roberts MG; Kiedrzynski T
Vaccine; 2017 Sep; 35(37):4913-4922. PubMed ID: 28802754
[TBL] [Abstract][Full Text] [Related]
2. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
[TBL] [Abstract][Full Text] [Related]
3. Measles vaccination in an increasingly immunized and developed world.
Hayman DTS
Hum Vaccin Immunother; 2019; 15(1):28-33. PubMed ID: 30156949
[TBL] [Abstract][Full Text] [Related]
4. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Hoshi SL; Kondo M; Okubo I
PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
[TBL] [Abstract][Full Text] [Related]
6. Measles control in developing and developed countries: the case for a two-dose policy.
Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
[TBL] [Abstract][Full Text] [Related]
7. The average cost of measles cases and adverse events following vaccination in industrialised countries.
Carabin H; Edmunds WJ; Kou U; van den Hof S; Nguyen VH
BMC Public Health; 2002 Sep; 2():22. PubMed ID: 12241559
[TBL] [Abstract][Full Text] [Related]
8. The cost saving opportunity of introducing a card review into measles-containing vaccination campaigns.
Hagedorn BL; Dabbagh A; McCarthy KA
Vaccine; 2019 Sep; 37(41):6093-6101. PubMed ID: 31471145
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
10. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
11. The effect of heterogeneity in uptake of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling study.
Glasser JW; Feng Z; Omer SB; Smith PJ; Rodewald LE
Lancet Infect Dis; 2016 May; 16(5):599-605. PubMed ID: 26852723
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria.
Oyo-Ita AE; Hanlon P; Nwankwo O; Bosch-Capblanch X; Arikpo D; Esu E; Auer C; Meremikwu M
PLoS One; 2021; 16(9):e0257277. PubMed ID: 34529714
[TBL] [Abstract][Full Text] [Related]
13. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
[TBL] [Abstract][Full Text] [Related]
14. Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza.
Ginsberg GM; Tulchinsky TH
J Epidemiol Community Health; 1990 Dec; 44(4):274-80. PubMed ID: 2126028
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Auckland 2014 measles outbreak indicates that adolescents and young adults could benefit from catch-up vaccination.
Reynolds G; Dias C; Thornley S; King R; Morrison A; Matson A; Hoskins R
N Z Med J; 2015 Sep; 128(1422):53-62. PubMed ID: 26411847
[TBL] [Abstract][Full Text] [Related]
16. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
17. [Estimate of the cost/benefit ratio of measles vaccination].
Cárdenas Ayala VM; Ruiz Matus C; Cabrera Coello L; Montesano Castellanos R; Garrido Lozada MT; Olvera Castillo R; Díaz Ortega JL
Salud Publica Mex; 1989; 31(6):735-44. PubMed ID: 2516660
[TBL] [Abstract][Full Text] [Related]
18. Measles immunity gaps and the progress towards elimination: a multi-country modelling analysis.
Trentini F; Poletti P; Merler S; Melegaro A
Lancet Infect Dis; 2017 Oct; 17(10):1089-1097. PubMed ID: 28807627
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness evaluation of measles immunization strategies on a college campus.
Shlian DM; Matchar D; Seymann GB
Fam Pract Res J; 1991 Jun; 11(2):193-207. PubMed ID: 1905455
[TBL] [Abstract][Full Text] [Related]
20. Vaccination for tomorrow: the need to improve immunisation rates.
Kassianos G
J Fam Health Care; 2010; 20(1):13-6. PubMed ID: 20397551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
